Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

PHASE4CompletedINTERVENTIONAL
Enrollment

944

Participants

Timeline

Start Date

September 12, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Influenza
Interventions
BIOLOGICAL

Flublok

0.5 mL intramuscular dose of Flublok

BIOLOGICAL

Flucelvax

0.5 mL intramuscular dose of Flucelvax

BIOLOGICAL

Fluarix

0.5 mL intramuscular dose of Fluarix

BIOLOGICAL

Fluzone

0.5 mL intramuscular dose of Fluzone

BIOLOGICAL

Fluzone High-Dose

0.5 mL intramuscular dose of Fluzone

Trial Locations (2)

76543

Baylor Scott and White Health, Temple

97227

Kaiser Permanente Northwest, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Baylor Scott and White Health

OTHER

collaborator

Kaiser Permanente

OTHER

collaborator

Abt Associates

INDUSTRY

lead

Centers for Disease Control and Prevention

FED

NCT03722589 - Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP | Biotech Hunter | Biotech Hunter